Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

BioGenex settles patent case with Ventana

BioGenex Laboratories announced a settlement of patent litigation with Ventana Medical Systems (VMSI), ending the dispute between the two companies.

3 Jun 2007

New findings on microRNAs

Over 30% of our genes are under the control of small molecules called microRNAs.

17 May 2007

Radically different approach to nuclear magnetic resonance

Detecting the molecular structure of a tiny protein using nuclear magnetic resonance (NMR) currently requires two things: a million-dollar machine the size of a massive SUV, and a large sample of the protein under study.

16 May 2007

Researchers develop first antibody that detects gene mutations that cause amyotrophic lateral sclerosis

Researchers at the University of Toronto's Faculty of Medicine have developed the first antibody that detects the only known cause of amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease.

9 May 2007

Current approach to drug discovery for Lou Gehrig's disease be re-examined

Most research on Lou Gehrig's disease therapeutics has been based on the assumption that its two forms (sporadic and hereditary) are similar in their underlying cause.

8 May 2007

Ranbaxy receives approval to manufacture Pravastatin Sodium tablets in U.S.

Ranbaxy Pharmaceuticals has announced that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Pravastatin Sodium Tablets (Pravastatin), 10 mg, 20 mg, 40 mg and 80 mg, with 180-day market exclusivity in the U.S. healthcare system for the 80 mg strength.

27 Apr 2007

Burnham awarded $7.39 million for study on Neuron-Glia communication in development

A team of researchers at the Burnham Institute for Medical Research (“Burnham”) has been awarded $7.39 million from the National Institute of Child Health and Human Development of the National Institutes of Health.

24 Apr 2007

Lexicon-Genentech reveals potential therapeutic targets

Lexicon Genetics Incorporated has announced that data was presented highlighting potential therapeutic targets related to its collaboration with Genentech, Inc. at the Society for Biomolecular Sciences 13th Annual Conference & Exhibition in Montreal, Canada.

19 Apr 2007

Lexicon Reports on anti-angiogenesis target discoveries

Lexicon Genetics has presented results from the company's genetic screen to identify proteins involved in blood vessel formation and organization.

18 Apr 2007

Thrombogenics announces agreement with Millipore for commercialization of stem cell technology

ThromboGenics NV has announced that it has completed a global license agreement with Millipore Corporation under which ThromboGenics will exclusively license its technology for production of the proprietary stem cell culture medium marketed by Millipore as RESGRO(x).

17 Apr 2007

Bristol-Myers Squibb announces new results of Baraclude (entecavir) resistance monitoring program

Bristol-Myers Squibb Company has announced new results of the Baraclude (entecavir) resistance monitoring program, which found a continued low incidence of resistance in studies of nucleoside-naive chronic hepatitis B patients through four years of treatment.

16 Apr 2007

Use of computer-assisted drug design in drug discovery

Metabasis Therapeutics has announced that on March 27, 2007 at the American Chemical Society 233rd National Meeting and Exposition in Chicago, Dr. M. Rami Reddy presented, "Use of Computer-Assisted Drug Design in Drug Discovery: Limitations and Advantages of Available Computational Methods."

15 Apr 2007

Alteon expands agreement with Biorap Technologies

Alteon has announced that it has entered into an expanded licensing agreement with BioRap Technologies, the commercialization arm of the Rappaport Family Institute for Research, Technion University, Israel, for all diagnostic devices or products for predictive purposes in vascular or cardiac diseases, including diagnostic assays for the measurement of the haptoglobin protein (Hp).

7 Apr 2007

Roche to acquire BioVeris

BioVeris Corporation has announced that the Company has reached a definitive agreement under which Roche will acquire BioVeris for $21.50 per share in cash, or a total of approximately $600 million.

From Roche Sequencing and Life Science 5 Apr 2007

Method for making new molecules based on flavonoids - implications for cancer therapeutics

You've heard of them -- the good-for-your-health compounds found in plants that we enjoy in red wine, dark chocolate, green tea and citrus fruits.

5 Apr 2007

Eli Lilly acquires Hypnion

Eli Lilly and Company has announced that it has completed its acquisition of Hypnion, Inc., a privately held neuroscience drug discovery company focused on sleep disorder research.

3 Apr 2007

First time observing real-time molecular interplay within ribosome

The ribosome is a kind of factory for protein in the cell, and as such has long been a prime target for drug discovery. Now, a technological advance by a team at Weill Cornell Medical College is poised to revolutionize research in the field.

21 Mar 2007

ARIUS Research granted two new U.S. patents for antibodies

ARIUS Research has announced that it has been granted two new United States patents for antibodies within their CD63 program. Patent 7,175,846. covers anti-cancer antibodies in ARIUS' partnered program for melanoma, breast and prostate cancers and protects the valuable site on the disease target that the drug candidate binds to.

8 Mar 2007

Lilly to acquire neuroscience drug discovery co. Hypnion

Eli Lilly and Company and Hypnion, Inc. today announced that they have signed a definitive merger agreement whereby Lilly will acquire Hypnion, a privately held neuroscience drug discovery company focused on sleep disorders.

5 Mar 2007

Fox Chase Cancer Center and Cancer Research Technology initiate drug discovery collaboration

Cancer Research Technology Inc. (CRT Inc.) and Fox Chase Cancer Center have announce the initiation of an oncology-focused drug discovery collaboration.

1 Mar 2007